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ABSTRACT
Background: Early identification of patients with coronavirus disease 2019 (COVID-19) who 
are at high risk of mortality is of vital importance for appropriate clinical decision making 
and delivering optimal treatment. We aimed to develop and validate a clinical risk score for 
predicting mortality at the time of admission of patients hospitalized with COVID-19.
Methods: Collaborating with the Korea Centers for Disease Control and Prevention (KCDC), 
we established a prospective consecutive cohort of 5,628 patients with confirmed COVID-19 
infection who were admitted to 120 hospitals in Korea between January 20, 2020, and April 
30, 2020. The cohort was randomly divided using a 7:3 ratio into a development (n = 3,940) 
and validation (n = 1,688) set. Clinical information and complete blood count (CBC) detected 
at admission were investigated using Least Absolute Shrinkage and Selection Operator 
(LASSO) and logistic regression to construct a predictive risk score (COVID-Mortality Score). 
The discriminative power of the risk model was assessed by calculating the area under the 
curve (AUC) of the receiver operating characteristic curves.
Results: The incidence of mortality was 4.3% in both the development and validation set. 
A COVID-Mortality Score consisting of age, sex, body mass index, combined comorbidity, 
clinical symptoms, and CBC was developed. AUCs of the scoring system were 0.96 (95% 
confidence interval [CI], 0.85–0.91) and 0.97 (95% CI, 0.84–0.93) in the development and 
validation set, respectively. If the model was optimized for > 90% sensitivity, accuracies were 
81.0% and 80.2% with sensitivities of 91.7% and 86.1% in the development and validation 
set, respectively. The optimized scoring system has been applied to the public online risk 
calculator (https://www.diseaseriskscore.com).
Conclusion: This clinically developed and validated COVID-Mortality Score, using clinical 
data available at the time of admission, will aid clinicians in predicting in-hospital mortality.
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INTRODUCTION
Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China in December 
2019, it was rapidly followed by worldwide outbreaks.1-3 As of March 22, 2021, the World 
Health Organization (WHO) reported a total of 123,877,740 COVID-19 cases globally, with 
an average mortality of 2.2%. In many patients, the disease is mild or self-limiting, however 
in a considerable portion the disease is severe and fatal. Consequently, it is vital to be able 
to identify in advance those patients who are at greatest risk of mortality, to enable prompt 
referral to appropriate care settings, to try and improve outcomes.
Recently, clinical scores to predict the occurrence of critically ill patients and/or a fatal 
outcome with COVID-19 were developed in a cohort of 1,590 Chinese patients treated in 
more than 575 centers throughout China.4 Liang et al.4 identified 10 independent predictive 
factors (abnormal chest radiograph, age, hemoptysis, dyspnea, unconsciousness, number 
of comorbidities, cancer history, neutrophil-to-lymphocyte ratio, lactate dehydrogenase and 
direct bilirubin) which were used to produce a risk score which had a mean area under the 
curve (AUC) of 0.88 in both the development (95% confidence interval [CI], 0.85–0.91), and 
validation cohort (95% CI, 0.84–0.93), for estimating the risk a hospitalized patient with 
COVID-19 will develop critical illness. Further reports have shown methods or new severity 
scores to assess disease severity and mortality of COVID-19 infection (Table 1).5-9 However, 
it is important to understand that the mortality of COVID-19 varies according to race and 
ethnicity, and therefore the accuracy of risk scores is not necessarily transferrable between 
countries.10 Therefore, the present study aimed to develop a novel COVID-19 in-hospital 
mortality risk score (hereafter referred to as COVID-Mortality Score), based on data rapidly 
obtainable soon after hospital admission in South Korea.
METHODS
Data sources and processing
We obtained medical records from laboratory-confirmed hospitalized cases with COVID-19 
reported to the Korea Centers for Disease Control and Prevention (KCDC) between January 
2020 and April 2020. All 120 hospitals in Korea that were assigned to treat COVID-19 patients 
submitted the clinical data of all their hospitalized cases with laboratory-confirmed COVID-19 
infection to the KCDC by April 30, 2020. All patients with COVID-19 were diagnosed and 
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Table 1. Current overview of COVID-19 severity or mortality prediction models
Author/setting/outcome Score variables Sample size (No. of 
participants for validation set)
Predictive performance
Liang et al.4/data from China, 
patients with confirmed 
COVID-19/in-hospital mortality
10 variables (chest radiographic abnormality, age, 
hemoptysis, dyspnea, unconsciousness, number of 
comorbidities, cancer history, neutrophil-to-lymphocyte 
ratio, lactate dehydrogenase, direct bilirubin)
1,590 (710) C index 0.88 (95% CI, 0.84–0.93)
Altschul et al.5/data from 
US, patients with confirmed 
COVID-19/in-hospital mortality
6 variables (age, oxygen saturation, mean arterial 
pressure, blood urea nitrogen, C-Reactive protein, 
international normalized ratio)
4,711 (2,356) C index 0.80 (95% CI, 0.79–0.82)
Gao et al.6/data from China, 
patients with confirmed 
COVID-19/in-hospital mortality
14 variables (age, sex, fever, sputum, consciousness, 
respiration rate, oxygen saturation, chronic kidney 
disease, number of comorbidities, platelet, blood urea 
nitrogen, D-dimer, albumin, lymphocyte)
2,520 (1,080) C index 0.96 (95% CI, 0.95–0.98)
Yadaw et al.9/data from US, 
patients with confirmed 
COVID-19/in-hospital mortality
3 variables (age, minimum oxygen saturation, type of 
patient encounter)
3,841 (1,210) C index 0.91 (95% CI, 0.88–0.94) 
(retrospective), 0.94 (95% CI, 
0.90–0.97) (prospective)
COVID-19 = coronavirus disease 2019, CI = confidence interval.
treated according to the guidelines published by the KCDC (http://www.cdc.go.kr). According 
to the KCDC guidelines, laboratory confirmation for COVID-19 infection was defined as a 
positive result on real-time reverse-transcription polymerase-chain-reaction assay of nasal and 
oropharyngeal swabs. All the patients analyzed either died in hospital or were discharged home 
despite the limitations that we could not acquire the information for in-hospital mortality due 
to other causes except COVID-19 or underlying diseases. We collected the data of all COVID-19 
patients on clinical status at hospitalization (clinical symptoms and signs, complete blood 
count (CBC) findings, disease severity, and discharge status). The patients' data were collected 
up to death or discharge from the hospital. Ordinary variables were converted into separated 
dichotomous variable. We randomly selected a development and validation set using a 7:3 ratio, 
respectively. Imputation for missing variables was considered if missing values were less than 
30%. We used predictive random forest algorithm for the imputation.
Potential predictive variables
The 35 potential predictive variables included the following patient characteristics at hospital 
admission: demographic variables and body mass index (BMI), medical history, clinical 
signs and symptoms, and CBC findings. Demographic variables such as age and sex and BMI 
were collected for the study. Medical history included diabetes mellitus, hypertension, heart 
failure, cardiovascular disease, bronchial asthma, chronic obstructive pulmonary disease, 
chronic renal disease, malignancy, chronic liver disease, autoimmune disease, and dementia. 
Clinical signs and symptoms included categorical and continuous variables as follows: 
systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body temperature, 
fever, cough, sputum, sore throat, rhinorrhea, myalgia, fatigue, dyspnea, headache, 
unconsciousness, nausea/vomiting, and diarrhea. CBC findings were included as follows: 
hemoglobin, hematocrit, lymphocyte, platelet, and white blood cell (WBC).
Outcomes
We adopted in-hospital death as the end point because death is the most serious outcome of 
COVID-19.
Selection of variables and construction of scoring system
We included all 3,940 patients hospitalized with COVID-19 in the development set for 
selection of variables and development of mortality score. As previously stated, the 35 
variables were involved in the selection process. Least Absolute Shrinkage and Selection 
Operator (LASSO) regression was used for the initial variable selection. For datasets with 
a low events per variables ratio, LASSO is more appropriate than the stepwise regression 
analysis, and it is more satisfactory for regression models with high-dimensional predictors. 
This is a logistic regression model that obtains the subset of predictors that minimized 
prediction error for a quantitative variable. In penalized regression, it is needed to specify 
a constant λ to adjust the amount of the coefficient shrinkage. With larger penalties, the 
estimates of weaker factors shrink toward zero so that only the strongest predictors remain in 
the model.1 We used LASSO regression augmented with 10-fold cross-validation for internal 
validation. The best covariates that minimized the cross-validation prediction error rate were 
defined as the minimum (λ min). The R package “glmnet” statistical software (R Foundation) 
was used to perform the LASSO regression. The variables identified by LASSO regression 
analysis that were independently significant in logistic regression analysis were used to 
generate the risk prediction model (COVID-Mortality Score). The COVID-Mortality Score 
was generated on the basis of coefficients from the logistic model. We used the following 
equation to estimate the probability: probability = exp(Σβ × X)/[1 + exp (Σβ × X)].
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Assessment of accuracy of prediction model
The accuracy of COVID-Mortality Score was analyzed for using the AUC of the receiver-
operator characteristic curve. For internal validation, we used 200 bootstrap resamplings. 
Statistical analysis was performed with R software (version 4.0.2, R Foundation), and P 
< 0.05 was considered statistically significant. To validate the generalizability of COVID-
Mortality Score, we used data from the 1,688 patients not included in the development set.
Ethics statement
This study was approved by the ethics committee of the Korea Centers for Disease Control 
and Prevention (KCDC) and written informed consent was exempted because of the de-
identified retrospective nature of the publicly available data.
RESULTS
Characteristics of the development set
In the development set, on hospital admission, 134 of 3,940 patients (3.4%) were admitted 
directly to the intensive care unit (ICU), with the rest (96.6%) admitted to the general ward. 
The end point of mortality occurred in 4.3% (n = 169). Patients who died were more likely 
to be men, and were more likely to have a BMI < 18.5, hypertension, an admission to the 
ICU and more comorbidities than those who lived (Table 2). Fever (23.1%), cough (42.0%), 
sputum (29.0%), sore throat (15.8%), rhinorrhea (10.9%), myalgia (16.3%), fatigue (4.0%), 
dyspnea (12.3%), headache (16.8%), unconsciousness (0.6%), nausea/vomiting (4.5%), 
and diarrhea (9.1%) were the commonest symptoms. CBC findings of the development 
set are also presented in Table 2. When CBC findings such as WBC, lymphocyte, platelet, 
and hemoglobin were evaluated as continuous variables, they did not exhibit a significant 
U-shaped pattern.
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Table 2. Clinical characteristics and complete blood cell findings among patients in the development set who did 
or did not develop mortality
Variables Total (n = 3,940) Alive (n = 3,771) Death (n = 169) P value
Age, yr < 0.001
0–9 44 (1.1) 44 (1.2) 0 (0.0)
10–19 150 (3.8) 150 (4.0) 0 (0.0)
20–29 789 (20.0) 789 (20.9) 0 (0.0)
30–39 384 (9.7) 383 (10.2) 1 (0.6)
40–49 509 (12.9) 508 (13.5) 1 (0.6)
50–59 806 (20.5) 796 (21.1) 10 (5.9)
60–69 654 (16.6) 631 (16.7) 23 (13.6)
70–79 368 (9.3) 316 (8.4) 52 (30.8)
≥ 80 236 (6.0) 154 (4.1) 82 (48.5)
Men 1,622 (41.2) 1,537 (40.8) 85 (50.3) 0.014
Body mass index, kg/m2 < 0.001
< 18.5 207 (5.3) 177 (4.7) 30 (17.8)
18.5–22.9 1,784 (45.3) 1,720 (45.6) 64 (37.9)
23.0–24.9 859 (21.8) 831 (22.0) 28 (16.6)
25.0–29.9 929 (23.6) 886 (23.5) 43 (25.4)
≥ 30.0 161 (4.1) 157 (4.2) 4 (2.4)
Systolic blood pressure, mmHg < 0.001
< 120 978 (24.8) 929 (24.6) 49 (29.0)
120–129 819 (20.8) 802 (21.3) 17 (10.1)
130–139 768 (19.5) 744 (19.7) 24 (14.2)
140–159 1,021 (25.9) 970 (25.7) 51 (30.2)
≥ 160 354 (9.0) 326 (8.6) 28 (16.6)
(continued to the next page)
Predictor selection
The 35 variables measured at hospital admission (Table 2, see method) were included 
in the LASSO regression. After LASSO regression selection (Supplementary Fig. 1), 17 
variables remained as significant predictors of death, including age, sex, BMI, SBP, heart 
rate, body temperature, comorbidities including rhinorrhea, dyspnea, unconsciousness, 
diabetes mellitus, hypertension, chronic obstructive pulmonary disease, malignancy, WBC, 
lymphocyte, platelet, and hemoglobin. Inclusion of these 17 variables in a logistic regression 
model resulted in 13 variables that were independently statistically significant predictors of 
death and was included in risk score. These variables included age by three groups: 60–69 
years (odds ratio [OR], 3.63; 95% CI, 1.64– 8.01; P = 0.001), age 70–79 years (OR, 6.12; 95% 
CI, 2.84–13.16; P < 0.001), age ≥ 80 years (OR, 21.24; 95% CI, 9.65–46.74; P < 0.001), men 
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Variables Total (n = 3,940) Alive (n = 3,771) Death (n = 169) P value
Diastolic blood pressure, mmHg 0.350
< 80 1,556 (39.5) 1,479 (39.2) 77 (45.6)
80–89 1,289 (32.7) 1,240 (32.9) 49 (29.0)
90–99 746 (18.9) 719 (19.1) 27 (16.0)
≥ 100 349 (8.9) 333 (8.8) 16 (9.5)
Heart rate, beats/min 86 ± 15 86 ± 15 89 ± 19 0.011
Body temperature, °C 36.9 ± 0.6 36.9 ± 0.5 37.0 ± 0.8 0.060
Duration of admission, days 25.6 ± 11.0 26.1 ± 10.6 14.4 ± 13.0 < 0.001
Admission site < 0.001
Intensive care unit 134 (3.4) 78 (2.1) 56 (33.1)
General ward 3,806 (96.6) 3,693 (97.9) 113 (66.9)
Comorbidity
Hypertension 829 (21.0) 726 (19.3) 103 (60.9) < 0.001
Diabetes mellitus 482 (12.2) 414 (11.0) 68 (40.2) < 0.001
Cardiovascular disease 139 (4.5) 116 (3.1) 23 (13.6) < 0.001
Bronchial asthma 85 (2.2) 75 (2.0) 10 (5.9) < 0.001
Chronic obstructive pulmonary disease 27 (0.7) 20 (0.5) 7 (4.1) < 0.001
Chronic renal disease 40 (1.0) 29 (0.8) 11 (6.5) < 0.001
Malignancy 101 (2.6) 88 (2.3) 13 (7.7) < 0.001
Chronic liver disease 60 (1.5) 54 (1.4) 6 (3.6) 0.028
Autoimmune disease 26 (0.7) 23 (0.6) 3 (1.8) 0.067
Dementia 173 (4.4) 116 (3.9) 57 (33.7) < 0.001
Symptoms at admission
Fever 909 (23.1) 851 (22.6) 58 (34.3) < 0.001
Cough 1,655 (42.0) 1,595 (42.3) 60 (35.5) 0.080
Sputum 1,142 (29.0) 1,089 (28.9) 53 (31.4) 0.486
Sore throat 623 (15.8) 613 (16.3) 10 (5.9) < 0.001
Rhinorrhea 428 (10.9) 424 (11.2) 4 (2.4) < 0.001
Myalgia 642 (16.3) 625 (16.6) 17 (10.1) 0.025
Fatigue 159 (4.0) 147 (3.9) 12 (7.1) 0.038
Dyspnea 483 (12.3) 399 (10.6) 84 (49.7) < 0.001
Headache 661 (16.8) 652 (17.3) 9 (5.3) < 0.001
Unconsciousness 25 (0.6) 6 (0.2) 19 (11.2) < 0.001
Nausea or vomiting 177 (4.5) 165 (4.4) 12 (7.1) 0.094
Diarrhea 357 (9.1) 342 (9.1) 15 (8.9) 0.932
Complete blood cell
WBC, µL 6,150 ± 2,481 6,058 ± 2,305 8,211 ± 4,544 < 0.001
Lymphocyte, % 29.7 ± 10.0 30.3 ± 9.7 15.0 ± 10.4 < 0.001
Platelet, µL 240,936 ± 71,765 243,403 ± 70,288 185,888 ± 81,881 < 0.001
Hemoglobin, g/dL 13.4 ± 1.6 13.5 ± 1.5 11.9 ± 2.1 < 0.001
Hematocrit, % 39.7 ± 4.5 39.9 ± 4.2 35.4 ± 6.4 < 0.001
Data are mean ± standard deviation or number (percentage), where No. is the total number of patients with 
available data.
WBC = white blood cell.
Table 2. (Continued) Clinical characteristics and complete blood cell findings among patients in the development 
set who did or did not develop mortality
(OR, 1.67; 95% CI, 1.04–2.67; P = 0.034), BMI < 18.5 (OR, 3.38; 95% CI, 1.64–6.95; P < 0.001), 
diabetes mellitus (OR, 2.10; 95% CI, 1.33–3.31; P = 0.001), malignancy history (OR, 2.78; 
95% CI, 1.14–6.79; P = 0.025), dementia (OR, 2.67; 95% CI, 1.49–4.78; P < 0.001), rhinorrhea 
(OR, 0.27; 95% CI, 0.08–0.91; P = 0.035), dyspnea (OR, 4.03; 95% CI, 2.50–6.48; P < 0.001), 
unconsciousness (OR, 25.10, 95% CI, 6.55–96.18; P < 0.001), WBC (OR per 103 μL, 1.10; 95% 
CI, 1.04–1.17, P < 0.001), lower lymphocyte proportion (OR per %, 0.92; 95% CI, 0.89–0.94; P 
< 0.001), lower platelet count (OR per 104 μL, 0.90; 95% CI, 0.88–0.93, P < 0.001), and lower 
hemoglobin level (OR per g/dL, 0.81; 95% CI, 0.72–0.92; P = 0.001) (Table 3).
The performance, validation and optimization of COVID-Mortality score
The clinical characteristics and CBC findings of the validation set are presented in 
Supplementary Table 1. The AUCs of the model with the development set and validation 
set were 0.97 (95% CI, 0.85–0.91, Fig. 1) and 0.96 (95% CI, 0.84–0.93, Fig. 2), respectively. 
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Table 3. Multivariable logistic regression model for predicting development of death in patients hospitalized with 
coronavirus disease 2019 in Korea
Variables OR 95% CI P value
Age 60–69 yr 3.63 1.64–8.01 0.001
Age 70–79 yr 6.12 2.84–13.16 < 0.001
Age ≥ 80 yr 21.24 9.65–46.74 < 0.001
Men 1.67 1.04–2.67 0.034
BMI < 18.5 3.38 1.64–6.95 < 0.001
Diabetes mellitus 2.10 1.33–3.31 0.001
Malignancy 2.78 1.14–6.79 0.025
Dementia 2.67 1.49–4.78 < 0.001
Rhinorrhea 0.27 0.08–0.91 0.035
Dyspnea 4.03 2.50–6.48 < 0.001
Unconsciousness 25.10 6.55–96.18 < 0.001
WBC, per 103 µL 1.10 1.04–1.17 < 0.001
Lymphocyte, per % 0.92 0.89–0.94 < 0.001
Platelet, per 104 µL 0.90 0.88–0.93 < 0.001
Hemoglobin, per g/dL 0.81 0.72–0.92 0.001
Each age group was compared with all other age groups.














Fig. 1. Receiver operating characteristic curve analysis in development set. Area under the curve of the COVID-19 
in-hospital mortality score in the 3,940 patients that constituted the development set.
When the scoring system was optimized for > 90% sensitivity by stratifying age groups, the 
accuracy was 81.0% with 91.7% sensitivity and 80.5% specificity in the development set. 
From the validation set, accuracy was 80.2% with 86.1% sensitivity and 80.0% specificity. 
The optimized scoring system was utilized for the construction of the online risk calculator 
(https://www.diseaseriskscore.com). The online risk calculator determined whether the 
patient belonged to high-risk group or low-risk group and presented hazard ratio and high 
rank percentage for mortality. The model-derived score thresholds used for the optimized 
scoring system were 0.51 for age less than 40, 0.00252 for age 40s, 0.00176 for age 50s, 
0.02302 for age 60s, 0.09532 for age 70s, and 0.13311 for age equal or more than 80.
DISCUSSION
This study developed and validated a clinical risk score (COVID-Mortality Score) to predict 
mortality among patients hospitalized with COVID-19 infection. Importantly the 13 variables 
required for calculating the risk of mortality using this score are all generally readily available 
on hospital admission. Practically, if the patient's estimated risk for death is low, the clinician 
may choose careful monitoring, whereas high-risk estimates might require aggressive 
treatment or immediate ICU care. In this context, we optimized the scoring model to achieve 
higher sensitivity, to the detriment of accuracy, given the potentially lethal clinical outcome 
of COVID-19.
Furthermore, this score-based model could assist clinicians when making decisions. For 
example, clinicians may treat patients with a high-risk score more intensively in an emergency, 
if resources and ICU beds were limited. Older age, sex, BMI, diabetes mellitus, malignancy, 
dementia, rhinorrhea, dyspnea, unconsciousness, WBC, lymphocyte, platelet, and hemoglobin 
were all included in the COVID-Mortality Score. Previous studies have found several of these 
variables to be risk factors for severe illness related to COVID-19 (Table 1). Wu et al.11 found 
that older age and more comorbidities were associated with a higher risk of developing acute 
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Fig. 2. Receiver operating characteristic curve analysis in validation set. Area under the curve of the COVID-19 
in-hospital mortality score in the 1,688 patients that constituted the validation set.
respiratory distress syndrome (ARDS) in patients infected with COVID-19. Recently Liang 
et al.4 developed a risk score based on characteristics of COVID-19 patients at the time of 
admission to the hospital to predict a patient's risk of developing a critical illness. They found 
that from 72 potential predictors, 10 variables were independent predictive factors and were 
included in a risk score which had a mean AUC of 0.88 in both the development (95% CI, 
0.85–0.91) and validation (95% CI, 0.84–0.93) cohorts. Some of the variables in the Chinese 
model such as age, dyspnea, unconsciousness, and cancer history were also included in the 
COVID-Mortality Score, and despite its development in a Korean population, which could 
limit its generalizability to other areas of the world, the present results show that the AUC 
is similar at 96 to 97%. Nevertheless, the current COVID-Mortality Score will be needed 
to validate externally with heterogenous baseline characteristics cohorts because of the 
limitation of only available predictors in current data.
While mortality prediction is neither perfect nor absolute, having a simple score to predict 
how severe a patient's illness is and their hospital course, will aid admitting and emergency 
room physicians in triaging the severity, and predicting the prognosis of COVID-19 infection, 
which we are realizing has a very broad-spectrum of severity. This can also be used to guide 
recommendations for palliative care consultations early in a patient's hospital course.
Although this study includes a large sample size for constructing the risk score and a 
relatively big sample for validation, the data for score development and validation are entirely 
from Korea and are limited only in specified predictors and mortality as outcomes, limiting 
the generalizability of the risk score in other areas of the world. However, despite these 
differences in race, the risk score remained valid in predicting in-hospital mortality.
In conclusion, we developed a risk score to estimate the risk of developing mortality among 
patients with COVID-19 based on 13 variables commonly measured on admission to hospital 
in this study. This score could help identify patients in need of more supportive treatment or 
assist with optimizing the use of medical resources.
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Supplementary Table 1
Clinical characteristics and complete blood cell findings among patients in the validation set 
who did or did not develop mortality
Click here to view
8/9https://jkms.org https://doi.org/10.3346/jkms.2021.36.e108
Risk Score to Predict Mortality from COVID-19
Supplementary Fig. 1
Feature selection using the least absolute shrinkage and selection operator (LASSO) binary 
logistic regression model. (A) LASSO coefficient profiles of the 35 baseline features. (B) 
Tuning parameter (λ) selection in the LASSO model used 10-fold cross-validation via 
minimum criteria.
Click here to view
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